Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
5.24
+0.08 (1.55%)
Dec 20, 2024, 4:00 PM EST - Market closed
Coya Therapeutics Revenue
Coya Therapeutics had revenue of $9.55M in the twelve months ending September 30, 2024. In the year 2023, Coya Therapeutics had annual revenue of $6.00M.
Revenue (ttm)
$9.55M
Revenue Growth
n/a
P/S Ratio
7.63
Revenue / Employee
$1,194,289
Employees
8
Market Cap
87.55M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 6.00M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCOYA News
- 3 days ago - Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD) - Business Wire
- 26 days ago - Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference - Business Wire
- 4 weeks ago - Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders - Business Wire
- 6 weeks ago - Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results - Business Wire
- 7 weeks ago - Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer - Business Wire
- 7 weeks ago - Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off - Seeking Alpha
- 7 weeks ago - Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study - Benzinga
- 7 weeks ago - Coya Therapeutics reports positive immune response, safety in mid-stage Alzheimer's drug trial - Reuters